Integra Lifesciences (IART) AI Stock Analysis

• Market Cap: $915.23M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: 4.99%
• EPS Growth: -7151.40%
• Country: US
• Employees: 4,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.54
• Shares Outstanding: 77,892,110
• 10 Day Avg. Volume: 1,157,285
• 30 Day Avg. Volume: 1,151,439
• PEG Ratio: 2.28
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 1.08
• P/FCF Ratio: 69.96
• Enterprise Value/Market Cap: 3.10
• Enterprise Value/Revenue: 1.73
• Enterprise Value/Gross Profit: 3.17
• Enterprise Value/Ebitda: -8.00
• 1Y Price Target: $12.33
• Price Target Upside: 4.94% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 6
• EPS Forecast (FY): 2.2
• Revenue Forecast (FY): $1.63B

• Rating: 45 Neutral
• Price Target: $11.00 ▼(-6.38% Downside)

Integra Lifesciences faces significant financial and operational challenges, reflected in its low financial performance and valuation scores. The technical analysis indicates bearish momentum, further weighing down the stock's outlook. While the earnings call highlighted some strategic advancements, the overall sentiment remains cautious due to ongoing disruptions and lowered guidance.

Positive Factors

Strong Operational Efficiency

Exceeding EPS guidance through operational efficiency and cost management indicates robust internal processes, supporting long-term profitability.

International Revenue Growth

Strong international growth, especially in China, suggests successful global expansion strategies, enhancing market position and revenue diversification.

Improved Manufacturing Yields

Significant improvements in manufacturing efficiency can lead to cost savings and better inventory management, strengthening supply chain resilience.

Negative Factors

Supply Chain Disruptions

Ongoing supply chain issues can hinder product availability and sales, affecting revenue consistency and customer satisfaction over the medium term.

Negative Profit Margins

Sustained negative profit margins indicate operational inefficiencies and financial strain, challenging the company's ability to generate sustainable profits.

Lowered Revenue Guidance

Reduced revenue guidance reflects challenges in meeting market expectations, potentially impacting investor confidence and strategic planning.

Integra Lifesciences Business Overview & Revenue Model

Company Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Integra Lifesciences generates revenue through a combination of its diverse product offerings, including advanced wound care products, neurosurgery instruments, and orthopedic implants. The company earns income by selling these products directly to hospitals, surgical centers, and healthcare providers. Key revenue streams include sales of regenerative tissue products, which are used in surgical procedures to promote healing and tissue regeneration, as well as sales from neurosurgical instruments and devices. Additionally, Integra benefits from strategic partnerships with other healthcare organizations and distributors that expand its market reach. The company's focus on innovation and its pipeline of new products also contribute significantly to its earnings potential, allowing it to address unmet medical needs and tap into new markets.

Integra Lifesciences Financial Statement Overview

Summary

Integra Lifesciences is facing significant financial challenges, particularly in profitability and cash flow generation. The negative net profit margin and deteriorating profitability metrics highlight operational inefficiencies. While there are improvements in leverage, the company needs to enhance its revenue and profit margins for sustainable growth.

Income Statement

Integra Lifesciences shows a concerning trend in its income statement. The TTM data reveals a negative net profit margin of -30.15%, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Despite a slight revenue growth of 1.31% in the TTM, the company's profitability metrics have deteriorated compared to previous years, highlighting a need for strategic adjustments.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio has improved to 0.21 in the TTM, suggesting better leverage management compared to previous years. However, the return on equity is negative at -38.51%, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio stands at a moderate level, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis shows challenges in maintaining positive free cash flow growth, with a significant decline of -281.61% in the TTM. The operating cash flow to net income ratio is 0.25, indicating limited cash flow generation relative to net income. However, the free cash flow to net income ratio is relatively strong at 0.78, suggesting some ability to convert earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.64B	1.61B	1.54B	1.56B	1.54B	1.37B
Gross Profit	895.93M	882.06M	888.39M	970.31M	944.64M	851.03M
EBITDA	-354.54M	193.29M	255.96M	384.60M	366.33M	267.93M
Net Income	-495.33M	-6.94M	67.74M	180.55M	169.07M	133.89M
Balance Sheet
Total Assets	3.65B	4.04B	3.78B	3.89B	3.78B	3.62B
Cash, Cash Equivalents and Short-Term Investments	267.88M	273.57M	309.10M	456.66M	513.45M	470.17M
Total Debt	213.51M	1.98B	1.68B	1.63B	1.67B	1.66B
Total Liabilities	2.61B	2.49B	2.19B	2.09B	2.10B	2.10B
Stockholders Equity	1.04B	1.55B	1.59B	1.80B	1.68B	1.51B
Cash Flow
Free Cash Flow	69.90M	24.96M	73.09M	217.38M	264.35M	139.94M
Operating Cash Flow	89.31M	129.38M	139.96M	264.47M	312.43M	203.83M
Investing Cash Flow	-77.41M	-390.81M	-94.18M	-58.58M	-161.44M	-68.07M
Financing Cash Flow	-3.16M	237.86M	-229.93M	-251.95M	-98.23M	121.63M

Integra Lifesciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Negative. The current price of 11.75 is below the 20-day moving average (MA) of 13.38, below the 50-day MA of 14.04, and below the 200-day MA of 15.94, indicating a bearish trend. The MACD of -0.74 indicates Positive momentum. The RSI at 37.12 is Neutral, neither overbought nor oversold. The STOCH value of 58.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IART.

Integra Lifesciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	76 Outperform	$1.79B	26.84	18.31%	―	29.47%	23.24%
CNMD	66 Neutral	$1.41B	12.91	6.60%	1.90%	4.69%	-51.57%
BVS	66 Neutral	$608.31M	65.45	4.97%	―	1.58%	―
AXGN	61 Neutral	$1.09B	―	-1.90%	―	18.72%	85.77%
OFIX	52 Neutral	$592.01M	-4.92	-24.60%	―	4.31%	3.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	45 Neutral	$915.23M	―	-38.71%	―	4.99%	-7151.40%

Integra Lifesciences Corporate Events

Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements

The recent earnings call for Integra LifeSciences presented a mixed sentiment, reflecting both operational successes and ongoing challenges. The company showcased strong operational efficiency and strategic advancements, such as the early relaunch of key products. However, these positives were tempered by supply chain disruptions, challenges in the ENT and Private Label segments, and a lowered full-year guidance, indicating a mixed performance overall.

Integra LifeSciences Reports Strong Q3 2025 Results

Integra LifeSciences Holdings Corporation, a global leader in medical technology, specializes in neurosurgery, tissue reconstruction, and surgical instrumentation, offering innovative solutions to healthcare professionals worldwide.

Integra LifeSciences’ Innovative Approach to Ulcer Treatment: A Study Update

Integra LifeSciences (IART) is conducting a multicenter, prospective, randomized, controlled platform trial titled ‘Multicenter, Prospective, Randomized, Controlled Platform Trial Assessing Clinical Utility of Cellular, Acellular and Matrix-like Products (CAMPs) and Standard of Care vs SOC Alone in Hard-to-Heal Diabetic Foot and Venous Leg Ulcers.’ The study aims to evaluate the effectiveness of multiple CAMPs and standard care compared to standard care alone in healing diabetic foot and venous leg ulcers.

Integra LifeSciences Advances with MIRROR Registry Study on Hematoma Evacuation

Integra LifeSciences is currently recruiting participants for its clinical study titled ‘The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation.’ The study aims to evaluate the effectiveness of the Aurora® Surgiscope in providing surgical access and visualization for the minimally invasive removal of hematoma in the brain. This research is significant as it explores various methods of hematoma removal based on surgeon preference and examines the impact of patient selection and timing of surgery.

Integra LifeSciences’ Pediatric Study: A Real-World Evaluation of the AERA® Device

Integra LifeSciences (IART) is conducting a study titled ‘A Real World, Observational Pediatric Registry of the Acclarent AERA® Eustachian Tube Balloon Dilation System.’ The study aims to gather real-world evidence on the clinical performance of the AERA® device in pediatric patients with Eustachian Tube Dysfunction. This research is significant as it seeks to confirm the device’s effectiveness in a real-world setting, potentially influencing treatment protocols for this condition.

Integra LifeSciences’ New Study on Burn Treatment: What Investors Need to Know

Study Overview: Integra LifeSciences is conducting an observational cohort analysis titled ‘An Observational Cohort Analysis of Tissue Quality of Integra Dermal Matrix (Integra®)-Treated Burns and NovoSorb® Biodegradable Temporizing Matrix (BTM)-Treated Burns 12-36 Months Post Final Skin Graft Application.’ The study aims to evaluate the tissue quality of burns treated with Integra and BTM, providing insights into their long-term effectiveness and patient outcomes.

Integra LifeSciences’ Bactiseal Catheter Safety Study: Key Insights for Investors

Integra LifeSciences is conducting a study titled ‘A Multi-center, Retrospective Registry Study on the Safety of Bactiseal Catheter’ to evaluate the safety of the Bactiseal catheter in patients with hydrocephalus. The study aims to monitor adverse events within two years post-implantation, providing crucial safety data for this medical device.

Integra LifeSciences’ CODMAN CERTAS Valve Study: Market Implications and Progress

Study Overview: Integra LifeSciences is conducting a post-market clinical follow-up study titled Post-Market Clinical Follow-up of Patients With CODMAN CERTAS Plus Programmable Valve. The study aims to assess the long-term performance and safety of the CODMAN CERTAS Plus Programmable Valve in patients with various conditions such as hydrocephalus and brain tumors. This study is significant as it provides valuable data on the device’s real-world effectiveness.